Last Updated: November 16, 2026

LYTENAVA Drug Profile

« Back to Dashboard


Summary for Tradename: LYTENAVA
High Confidence Patents:0
Applicants:1
BLAs:1
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for LYTENAVA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for LYTENAVA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for LYTENAVA Derived from Patent Text Search

No patents found based on company disclosures

LYTENAVA Market Dynamics and Financial Trajectory: Outlook Therapeutics’ Ophthalmic Bevacizumab

Last updated: August 26, 2026

LYTENAVA, formerly ONS-5010, is Outlook Therapeutics’ ophthalmic formulation of bevacizumab for retinal diseases. Its commercial opportunity depends on replacing physician-administered compounded bevacizumab in wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion. The product has potential pricing and distribution advantages, but its value remains constrained by regulatory execution, payer adoption, established anti-VEGF competitors and Outlook Therapeutics’ need for continued external financing.

This assessment reflects public information available through June 2024.

What is LYTENAVA and how does its product strategy work?

LYTENAVA is a sterile, ophthalmic formulation of bevacizumab intended for intravitreal injection. Bevacizumab is already widely used off label in ophthalmology after compounding into single-use syringes. LYTENAVA is designed to provide a commercially manufactured, FDA-reviewed alternative.

Attribute LYTENAVA
Active ingredient Bevacizumab
Developer Outlook Therapeutics Inc.
Former development name ONS-5010
Route Intravitreal injection
Regulatory pathway Biologics license application under section 351(a)
Primary commercial target Retinal vascular diseases
Principal substitute Compounded bevacizumab
Branded competitors Eylea, Eylea HD, Vabysmo, Lucentis, Beovu
Regulatory status through June 2024 Not FDA approved
Orange Book status No Orange Book listing expected for an unapproved biologic
Purple Book relevance Bevacizumab reference products and biosimilars are listed separately from LYTENAVA

The commercial argument is based on manufacturing quality, sterility controls, supply consistency, labeling and possible reimbursement advantages. The product does not rely on a new molecular entity or a novel biologic mechanism.

What is the FDA status of LYTENAVA?

LYTENAVA has not received FDA approval through June 2024. Outlook Therapeutics submitted a BLA based on clinical and manufacturing data intended to support ophthalmic bevacizumab use.

The FDA issued a complete response letter in August 2023. The agency’s action prevented approval at that time and required Outlook Therapeutics to address deficiencies before resubmission. The company’s subsequent regulatory strategy focused on additional manufacturing and process-related work, together with responses to FDA requirements.

LYTENAVA regulatory timeline

Date Event
2019-2021 Outlook Therapeutics advanced ONS-5010 through ophthalmic clinical development
2022 Company submitted its BLA to FDA
2023 FDA accepted the application for review
August 2023 FDA issued a complete response letter
2023-2024 Outlook Therapeutics worked on manufacturing, quality and regulatory deficiencies
Through June 2024 FDA approval had not been granted

The FDA status is the central near-term value driver. Every commercial forecast depends on approval, a usable label and an acceptable manufacturing inspection outcome.

When could LYTENAVA lose exclusivity?

LYTENAVA’s exclusivity profile is different from that of a conventional new chemical entity. Bevacizumab has been commercially available for years, and the active ingredient is no longer protected by basic composition-of-matter exclusivity.

The product’s protection would instead rely on:

  • Biologic reference-product exclusivity, if available under the applicable regulatory framework.
  • Formulation and manufacturing patents.
  • Device, container-closure and packaging claims.
  • Method-of-use patents covering ophthalmic administration.
  • Regulatory and commercial barriers associated with an FDA-approved ophthalmic presentation.
  • Brand, supply-chain and payer contracts.

Because LYTENAVA is a proposed ophthalmic formulation of an established biologic, patent expiration alone is unlikely to determine market entry. A competing manufacturer could seek to develop another ophthalmic bevacizumab product or continue supplying compounded bevacizumab. The principal legal question is whether Outlook’s claims cover a commercially meaningful formulation or manufacturing process that competitors cannot readily design around.

What patents protect LYTENAVA?

Public company disclosures describe intellectual-property protection for ONS-5010 and its ophthalmic formulation. The most relevant categories are formulation, manufacturing, stability, container-closure and administration claims.

The exact commercial strength of the estate depends on claim scope and enforceability. Patents directed narrowly to a particular concentration, excipient combination or filling process may provide useful protection against direct copying but may not block all alternative ophthalmic bevacizumab products.

A complete patent-by-patent validity assessment requires review of issued claims, prosecution history, terminal disclaimers, assignment records and continuation status. The key business conclusion is that LYTENAVA’s moat is likely to be narrower than the moat surrounding a novel anti-VEGF biologic.

What is the competitive landscape for LYTENAVA?

LYTENAVA would enter a highly competitive anti-VEGF market. The largest commercial products are aflibercept products from Regeneron and Bayer, faricimab from Roche and ranibizumab from Genentech. Biosimilar and interchangeable competition is expanding around several established biologics.

Product Active ingredient Company Main competitive position
LYTENAVA Bevacizumab Outlook Therapeutics FDA-reviewed ophthalmic bevacizumab, if approved
Avastin Bevacizumab Genentech/Roche Off-label compounded standard
Eylea Aflibercept Regeneron/Bayer Established branded anti-VEGF
Eylea HD High-dose aflibercept Regeneron/Bayer Longer-interval dosing option
Vabysmo Faricimab Roche/Genentech Dual-pathway mechanism and extended dosing
Lucentis Ranibizumab Genentech Legacy branded anti-VEGF
Beovu Brolucizumab Novartis Longer-interval positioning with safety limitations
Biosimilar bevacizumab Bevacizumab Multiple manufacturers Oncology-approved products, not automatically ophthalmic substitutes

The most important competitor is not another branded drug. It is compounded bevacizumab, which is inexpensive and already familiar to retina specialists. LYTENAVA must persuade physicians, hospitals and payers that the benefits of a commercial ophthalmic product justify a higher acquisition cost.

How large is the addressable market for LYTENAVA?

The addressable market is the U.S. ophthalmic use of bevacizumab in retinal disease, not the entire global bevacizumab market. The product’s potential volume is substantial because bevacizumab is used extensively in retinal practice, but the value capture per injection is uncertain.

Market size depends on four variables:

  1. The number of intravitreal injections performed annually.
  2. The percentage currently using compounded bevacizumab.
  3. The price premium LYTENAVA can sustain.
  4. The extent to which payers reimburse it as a branded or physician-administered biologic.

Compounded bevacizumab has a major cost advantage. In many settings, the drug cost per dose is a small fraction of branded anti-VEGF products. LYTENAVA’s commercial value therefore depends on converting a low-cost procedure supply into a reimbursed FDA-approved product.

Which patients are most relevant?

The initial target population includes patients with:

  • Neovascular age-related macular degeneration.
  • Diabetic macular edema.
  • Macular edema following retinal vein occlusion.

These indications have large patient populations and established anti-VEGF treatment pathways. The principal adoption opportunity is among practices that use compounded bevacizumab but want an approved, ready-to-use product with controlled sterility and supply.

What are the main market dynamics affecting LYTENAVA?

Compounded bevacizumab sets a low price ceiling

Compounded Avastin is the reference point for economic discussions. Physicians and ambulatory surgery centers may resist a large premium unless LYTENAVA reduces operational risk, wastage, adverse-event exposure or administrative complexity.

Branded anti-VEGF products control premium reimbursement

Eylea, Vabysmo and other branded products compete through efficacy, dosing intervals, manufacturer support and established payer access. LYTENAVA is unlikely to displace these products broadly at launch. Its more realistic opportunity is conversion from compounded bevacizumab.

FDA approval could change physician risk calculations

An approved ophthalmic label could reduce concerns about compounding, sterility, traceability and preparation variability. Those benefits may matter most to large retina groups, integrated delivery networks and hospital systems.

Supply reliability is commercially important

Outlook must establish reliable manufacturing and distribution. A product intended to replace compounded supply cannot tolerate frequent shortages or limited geographic availability.

Payer policy will determine net price

LYTENAVA would likely be administered in physician offices and reimbursed under a medical benefit. Coverage, buy-and-bill economics, acquisition cost, average sales price treatment and prior authorization requirements will influence uptake.

What is Outlook Therapeutics’ financial trajectory?

Outlook Therapeutics has historically operated as a development-stage company with limited or no product revenue. Its financial profile has been defined by clinical development costs, regulatory expenses, manufacturing work, general and administrative spending and recurring capital raises.

Financial factor Effect on Outlook Therapeutics
Product revenue Limited or absent before LYTENAVA approval
Operating expenses Driven by regulatory, manufacturing and commercial preparation
Cash burn Persistent while approval and launch remain pending
Funding requirement High, particularly after the FDA complete response letter
Dilution risk Material because equity financing may be required
Commercial inflection point FDA approval followed by launch and reimbursement
Downside risk Further regulatory delay, rejection or weak payer uptake

The 2023 FDA response increased the company’s financing burden because it delayed revenue generation while requiring additional regulatory and manufacturing expenditures. Outlook’s financial trajectory therefore has a binary structure:

  • Before approval: continued cash consumption and financing dependence.
  • After approval: launch costs, inventory investment, sales-force expenses and market-access spending.
  • After commercial traction: potential operating leverage if LYTENAVA captures a meaningful share of compounded bevacizumab use.

The first post-approval quarters would likely show substantial expenses before revenue reaches scale. A launch requires manufacturing validation, inventory, specialty distribution, medical-affairs activity, payer contracting and physician education.

What generic or biosimilar entry risks exist for LYTENAVA?

LYTENAVA would not be protected from competition simply because it is a biologic. Bevacizumab biosimilars already exist in the U.S. oncology market, including products such as Mvasi, Zirabev, Alymsys and Vegzelma. Those products are not automatically interchangeable with an ophthalmic bevacizumab presentation, and their labels and handling requirements differ.

The competitive risks include:

  • A competing ophthalmic bevacizumab formulation.
  • Continued use of compounded Avastin.
  • Expanded use of biosimilar bevacizumab through compounding channels, subject to applicable law.
  • Physician preference for aflibercept or faricimab.
  • Contracting pressure from large retina practices.
  • Patent challenges against formulation or manufacturing claims.

A conventional Paragraph IV challenge is not the primary pathway for an approved biologic. Biologic competitors generally use the abbreviated pathway under the Biologics Price Competition and Innovation Act, with patent-resolution procedures distinct from Hatch-Waxman litigation. LYTENAVA has no Orange Book listing through June 2024 because it was not FDA approved as a drug product under the Orange Book framework.

What patent litigation and settlement risks affect LYTENAVA?

No major public LYTENAVA patent settlement or Paragraph IV dispute had established commercial significance through June 2024. The principal legal risks are likely to arise after approval, when the product’s commercial value becomes large enough to attract competing ophthalmic formulations.

Potential disputes could concern:

  • Whether a competing formulation infringes Outlook’s formulation claims.
  • Whether Outlook’s patents are enabled and sufficiently supported.
  • Whether manufacturing claims cover common sterile-fill processes.
  • Whether competitors can design around the claimed excipients or concentration.
  • Whether biologic competition triggers BPCIA patent litigation.

The absence of a public settlement does not eliminate competition risk. It means the key barriers remain regulatory, manufacturing and commercial rather than litigation-driven.

How does LYTENAVA compare with Eylea and Vabysmo?

Factor LYTENAVA Eylea Vabysmo
Active ingredient Bevacizumab Aflibercept Faricimab
Status through June 2024 Not approved Approved Approved
Primary differentiation Approved ophthalmic presentation of low-cost molecule Established efficacy and retinal-market scale Extended dosing and dual-target mechanism
Main price pressure Compounded Avastin Biosimilars and branded competition Established anti-VEGF alternatives
Commercial buyer Retina practices and medical-benefit payers Retina practices and payers Retina practices and payers
Key launch requirement Regulatory approval and conversion from compounding Defend share and pricing Expand adoption and dosing advantage
Patent position Formulation and process dependent Product and formulation estate Product, formulation and method-of-use estate

LYTENAVA’s advantage is cost-originated demand from compounded bevacizumab. Its disadvantage is that the same low-cost alternative limits pricing power. Eylea and Vabysmo have stronger established commercial positions, broader physician experience and approved labels.

What geographic markets can LYTENAVA address?

The United States is the primary near-term market because Outlook’s regulatory and commercial strategy is centered on FDA approval. International expansion would require separate regulatory submissions, manufacturing arrangements and reimbursement negotiations.

The most attractive U.S. customers are likely to be:

  • High-volume retina practices.
  • Hospital outpatient departments.
  • Integrated delivery networks.
  • Specialty pharmacies and distributors serving ophthalmology.
  • Payers seeking lower-cost alternatives to branded anti-VEGF therapies.

International markets may offer opportunities, but pricing and compounding practices vary materially by country. European, Canadian and Asian commercialization would require a separate evidence and market-access strategy.

What generic launch scenarios exist for LYTENAVA?

Base case

FDA approval is followed by gradual conversion from compounded bevacizumab. Outlook secures specialty distribution and achieves moderate adoption among retina practices. Revenue grows, but the company remains dependent on external capital during the initial launch period.

Upside case

LYTENAVA receives a commercially useful label, establishes reliable supply and obtains favorable reimbursement. Large retina groups shift substantial volume from compounding, producing rapid unit growth and operating leverage.

Downside case

Regulatory delays continue, manufacturing issues recur or payer reimbursement is inadequate. Physicians retain compounded bevacizumab, while Eylea, Eylea HD and Vabysmo absorb patients requiring branded therapies. Outlook raises capital without reaching sustainable commercial scale.

How strong is the LYTENAVA investment and patent profile?

LYTENAVA has a credible market need but a constrained strategic moat. Its strongest assets are the potential FDA-approved ophthalmic presentation, manufacturing controls and access to a large existing bevacizumab treatment base. Its weakest points are the absence of molecular novelty, heavy dependence on FDA execution, low-cost compounded competition and financing requirements.

The financial profile is therefore high-risk and milestone-driven. FDA approval would materially improve the company’s strategic position, but approval alone would not establish commercial success. The product must also demonstrate reliable supply, reimbursement acceptance and sufficient physician willingness to pay for a regulated alternative to compounding.

Key Takeaways

  • LYTENAVA is Outlook Therapeutics’ proposed ophthalmic formulation of bevacizumab.
  • Its primary commercial target is compounded Avastin, not only branded anti-VEGF products.
  • FDA approval had not been obtained through June 2024 after a complete response letter in August 2023.
  • The product has no Orange Book listing in its unapproved status.
  • Patent value is concentrated in formulation, manufacturing and use claims rather than molecular composition.
  • Outlook’s financial trajectory remains dependent on external funding until approval and revenue scale.
  • Existing bevacizumab biosimilars create long-term competitive pressure, although they are not automatically interchangeable with an ophthalmic formulation.
  • The most important launch risks are regulatory execution, supply reliability, reimbursement and physician conversion from compounding.
  • LYTENAVA’s upside is meaningful if it captures high-volume retina practices, but its pricing power is limited by the low cost of compounded bevacizumab.

FAQs About LYTENAVA

Is LYTENAVA the same drug as Avastin?

LYTENAVA and Avastin contain bevacizumab, but LYTENAVA is intended to be a commercially manufactured ophthalmic formulation for intravitreal use. Avastin is approved for oncology indications and is commonly compounded for ophthalmic use.

Does LYTENAVA have an Orange Book patent listing?

No Orange Book listing had been established through June 2024 because LYTENAVA had not received FDA approval. Biologic patent and reference-product information is handled through regulatory frameworks that differ from conventional small-molecule Orange Book listings.

Can bevacizumab biosimilars replace LYTENAVA?

Not automatically. Biosimilars approved for oncology use may have different labels, presentations and handling requirements. Substitution depends on FDA status, state law, payer policy and the specific ophthalmic use.

What would make LYTENAVA commercially successful?

Approval, a reliable supply chain, favorable medical-benefit reimbursement and conversion of retina practices from compounded bevacizumab are the main requirements. A large price premium over compounded product would make adoption more difficult.

Is Outlook Therapeutics financially dependent on LYTENAVA?

Yes. Through June 2024, Outlook Therapeutics remained a development-stage company with limited product revenue and continuing operating expenses. LYTENAVA approval and commercial launch were the company’s principal potential sources of future operating revenue.

References

  1. U.S. Food and Drug Administration. (2023). Complete response letter for ONS-5010 biologics license application. FDA.

  2. U.S. Food and Drug Administration. (2024). Purple Book: Lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. FDA. https://purplebooksearch.fda.gov/

  3. Genentech. (2024). Avastin prescribing information. Roche/Genentech.

  4. Regeneron Pharmaceuticals, Inc. (2024). Eylea and Eylea HD prescribing information. Regeneron Pharmaceuticals.

  5. Genentech. (2024). Vabysmo prescribing information. Roche/Genentech.

  6. Outlook Therapeutics, Inc. (2023). Annual report on Form 10-K for the fiscal year ended September 30, 2023. U.S. Securities and Exchange Commission.

  7. Outlook Therapeutics, Inc. (2024). Quarterly report on Form 10-Q. U.S. Securities and Exchange Commission.

  8. U.S. Securities and Exchange Commission. (2024). Outlook Therapeutics, Inc. company filings. https://www.sec.gov/edgar/browse/?CIK=1649989

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.